Abbott Molecular is an experienced global health care partner and a proven leader in successful companion diagnostic development.
Abbott Molecular provides physicians with critical information based on the early detection of pathogens and subtle changes in patients' genes and chromosomes, allowing for earlier diagnosis, selection of appropriate therapies and monitoring of disease progression. The product portfolio includes instruments and reagents used to conduct sophisticated analysis of patient DNA and RNA through Real-Time PCR, FISH and Sequencing Technologies.
One Partner. A Total Solution. www.abbottmolecular.com
Deallus Group Expertise Partner Deallus Group are a global life-sciences management consultancy, specialising in strategy and competitive analysis. They provide innovative strategy consulting and competitive insights for industry leaders who define, lead and inform brand, franchise and corporate management in life science organizations. www.deallusgroup.com
Definiens Expertise Partner Definiens is the leading provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens is headquartered in Munich, Germany, and has offices throughout the United States. www.definiens.com
Asuragen Conference Partner Asuragen is a molecular diagnostic company focused on personalizing oncology treatment through the development of clinically useful diagnostics for both pathological diagnosis and as companions to therapy. Asuragen’s diagnostic development leverages a number of genomic research technologies, including next generation sequencing, microarrays, qPCR, Luminex, and more. Asuragen has developed a targeted deep sequencing methodology for mutation detection that is highly optimized for clinical specimens, enabling accurate detection of low-level variants. Targeted high depth sequencing of clinically actionable mutations in FFPE and FNA tumor biopsies offers more comprehensive and sensitive profiling of tumors with implications for more effective and timely targeted therapies. www.asuragen.com
PrimeraDx Spotlight Partner PrimeraDx is a molecular diagnostics company that has developed a game-changing clinical platform which combines PCR with capillary electrophoresis. The result of combining these two technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative, answers to the clinic. The company is pursuing a two-pronged strategy to sell the system to clinical labs and to collaborate with pharmaceutical companies to develop high-value companion diagnostic products. Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes. PrimeraDx’s technology represents the next generation of quantitative PCR. www.primeradx.com